Discover how parecoxib sodium is utilized for short-term postoperative pain control across Europe, focusing on its effectiveness and clinical applications.
Upon intravenous or intramuscular administration, parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib. Valdecoxib selectively binds to and inhibits COX-2. This prevents the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever. This NSAID does not inhibit COX-1 at therapeutic concentrations and, therefore, does not interfere with blood coagulation.
COX-1, a constitutive enzyme, plays a major role in the release of PG to regulate hemostasis. COX-2, an inducible enzyme, releases PG that mediates pain, inflammation, and fever. Nonselective NSAIDs inhibit both forms of COX.
When given at the recommended doses for management of acute pain, the onset of analgesia was 7–14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours. Learn more: parecoxib sodium.
Add your comment